- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03463148
Validation of a Sensor for Non-Invasive Measurements
January 19, 2022 updated by: Baxter Healthcare Corporation
Validation of a Sensor for Non-Invasive Measurement of Vital Signs, Hemodynamic Parameters and Time-Dependent Physiological Waveforms
Subjects will be measured with both a sensor and a reference device
Study Overview
Status
Completed
Conditions
Detailed Description
Subjects will participate in a study measuring a single set of paired values.
In this case, measurements will take roughly 2-30 minutes to complete, and will involve: 1) attaching the sensor on the subject; 2) attaching one or more reference devices to the subject; 3) making measurements with both the sensor and reference device, either simultaneously or sequentially; and 4) collecting and analyzing the paired value.
Study Type
Observational
Enrollment (Actual)
136
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92121
- toSense, Inc. Headquarters
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Men and women over 22 years of age
Description
Inclusion Criteria:
- Subject is at least 18 (eighteen) years of age at screening.
- Subject and/or legally authorized person/representative is willing to undergo the Informed Consent process prior to enrollment in the study.
- Subject selection will not be based on age, height, or weight.
- Subject is a candidate for this study based on the PI's opinion and knowledge of the subject's condition as well as the features of the investigational device tested during the study.
Exclusion Criteria:
- Subject is participating in another clinical study that may affect the results of either study.
- Subjects that are pregnant will not be included in the study.
- Subject is unable or not willing to wear electrode patches as required for a period of up to 168 hours.
- Subject is considered by the Principal Investigator to be medically unsuitable for study participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
1
Men/Women who meet the inclusion/exclusion criteria of this protocol.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of Blood Pressure Measurement from Sensor with Human Auscultation measurement of Blood Pressure.
Time Frame: 3-36 Months
|
Comparison of Blood Pressure Measurement from Sensor with Human Auscultation measurement of Blood Pressure.
Specifically, Systolic Blood Pressure and Diastolic Blood Pressure with units of millimeters of mercury (mmHg) will be compared.
|
3-36 Months
|
|
Fluids
Time Frame: 3-36 Months
|
Observation of fluid measurement from Sensor (ohms)
|
3-36 Months
|
|
Heart Rate
Time Frame: 3-36 Months
|
Observation of heart rate measurement from Sensor (beats/min)
|
3-36 Months
|
|
Heart Rate Variability
Time Frame: 3-36 Months
|
Observation of heart rate variability from Sensor (milliseconds)
|
3-36 Months
|
|
Respiration Rate
Time Frame: 3-36 Months
|
Observation of respiration rate from Sensor (breaths/min)
|
3-36 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Matthew Banet, PhD, Baxter Healthcare Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 24, 2017
Primary Completion (Actual)
April 19, 2021
Study Completion (Actual)
April 19, 2021
Study Registration Dates
First Submitted
January 31, 2018
First Submitted That Met QC Criteria
March 9, 2018
First Posted (Actual)
March 13, 2018
Study Record Updates
Last Update Posted (Actual)
January 20, 2022
Last Update Submitted That Met QC Criteria
January 19, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TS-IRB-0003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)